Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
Proteomics analysis has been heralded as a novel tool for identifying new and specific biomarkers that may improve diagnosis and monitoring of various disease states. Recent years have brought a number of proteomics profiling technologies. Although proteomics profiling has resulted in the detection of disease-associated differences and modification of proteins, current proteomics technologies display certain limitations that are hampering the introduction of these new technologies into clinical laboratory diagnostics and routine applications. In this review, we summarize current advances in mass spectrometry based biomarker discovery. The promises and challenges of this new technology are discussed with particular emphasis on diagnostic perspectives of mass-spectrometry based proteomics profiling for malignant diseases.
Findeisen
Peter
P
Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany. peter.findeisen@ikc.ma.uni-heidelberg.de
Neumaier
Michael
M
D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood / Q000652:urine; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods* / Q000639:trends; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000652:urine; D020543:Proteome / Q000032:analysis*; D040901:Proteomics / Q000379:methods* / Q000639:trends
D014408:Biomarkers, Tumor; D020543:Proteome